Atypical Hemolytic Uremic Syndrome Ahus clinical trials

Explore recruiting atypical hemolytic uremic syndrome ahus clinical trials.

Recruiting atypical hemolytic uremic syndrome ahus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atypical Hemolytic Uremic Syndrome Ahus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS)

Germany, Hungary, Spain, Poland, Italy, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Belgium, Spain, Italy, France, Hungary, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, single arm, open-label study to evaluate efficacy and safety of switching from anti-C5 antibody therapy to iptacopan therapy in study participants with aHUS

Italy, Spain, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, single arm, open-label extension study to evaluate the long-term safety, tolerability and efficacy of iptacopan in participants with atypical hemolytic uremic syndrome (aHUS) who have completed a preceding iptacopan phase 3 study in aHUS

Czechia, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab Administered Subcutaneously in Pediatric Participants (2 to < 18 years of age) with Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hemolytic Uremic Syndrome (aHUS)

Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Atypical Hemolytic Uremic Syndrome Ahus trials by city

Atypical Hemolytic Uremic Syndrome Ahus in Toronto Atypical Hemolytic Uremic Syndrome Ahus in Vancouver Atypical Hemolytic Uremic Syndrome Ahus in Montreal Atypical Hemolytic Uremic Syndrome Ahus in Calgary Atypical Hemolytic Uremic Syndrome Ahus in Edmonton Atypical Hemolytic Uremic Syndrome Ahus in Ottawa Atypical Hemolytic Uremic Syndrome Ahus in Winnipeg Atypical Hemolytic Uremic Syndrome Ahus in Quebec City Atypical Hemolytic Uremic Syndrome Ahus in Hamilton Atypical Hemolytic Uremic Syndrome Ahus in Kitchener Atypical Hemolytic Uremic Syndrome Ahus in London Atypical Hemolytic Uremic Syndrome Ahus in Halifax Atypical Hemolytic Uremic Syndrome Ahus in New York Atypical Hemolytic Uremic Syndrome Ahus in Los Angeles Atypical Hemolytic Uremic Syndrome Ahus in Chicago Atypical Hemolytic Uremic Syndrome Ahus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease